Key result
Diabetic cardiomyopathy is a frequently underdiagnosed complication of diabetes mellitus that requires the identification of clear pathophysiological landmarks and potential therapeutic targets.
Diabetic cardiomyopathy is an increasingly recognized, often underdiagnosed complication of diabetes requiring better diagnostic and therapeutic strategies.
DCM warrants clinical vigilance for HF risk in diabetes; leaves open targeted early detection and therapies.
Although ischemic heart disease is the major cause of death in diabetic patients, diabetic cardiomyopathy (DCM) is increasingly recognized as a clinically relevant entity. Considering that it comprises a variety of mechanisms and effects on cardiac function, increasing the risk of heart failure and worsening the prognosis of this patient category, DCM represents an important complication of diabetes mellitus, with a silent development in its earlier stages, involving intricate pathophysiological mechanisms, including oxidative stress, defective calcium handling, altered mitochondrial function, remodeling of the extracellular matrix, and consequent deficient cardiomyocyte contractility. While DCM is common in diabetic asymptomatic patients, it is frequently underdiagnosed, due to few diagnostic possibilities in its early stages. Moreover, since a strategy for prevention and treatment in order to improve the prognosis of DCM has not been established, it is important to identify clear pathophysiological landmarks, to pinpoint the available diagnostic possibilities and to spot potential therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Gîlcă-Blanariu et al. (2017) conducted a review in Diabetic cardiomyopathy. Diabetic cardiomyopathy is a frequently underdiagnosed complication of diabetes mellitus that requires the identification of clear pathophysiological landmarks and potential therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: